Breaking News

Altus, Lonza Sign Manufacturing Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Altus Pharmaceuticals, Inc. has signed a long-term agreement with Lonza Group Ltd. for the commercial manufacture of its ALTU-135 drug substances at Lonza’s facility in Kourim, Czech Republic. ALTU-135 is an orally administered enzyme replacement therapy in development for patients with pancreatic insufficiency. The drug product that results after blending three drug substance enzymes: protease, lipase and amylase. This combination is designed to improve fat, protein and carbohydrate absor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters